Celcuity (NASDAQ:CELC) Shares Down 5.4% - What's Next?

Key Points

• Celcuity shares fell 5.4% on Friday to about $117.90, with trading volume roughly 133,754 shares — down ~81% from the average daily volume of 719,131.
• Analysts hold a consensus rating of Moderate Buy (8 Buys, 1 Hold, 1 Sell) with an average price target of $109.88, although individual targets range roughly from $110 to $126.
• Company insiders have been selling (directors sold 3,000 and 20,000 shares), leaving insiders with 15.77% ownership; Celcuity is a clinical-stage precision oncology biotech with a $5.67B market cap and negative earnings (last quarter EPS -$0.97, beating estimates).

Celcuity, Inc. (NASDAQ:CELC - Get Free Report)'s share price dropped 5.4% during trading on Friday . The stock traded as low as $118.77 and last traded at $117.8950. Approximately 133,754 shares traded hands during trading, a decline of 81% from the average daily volume of 719,131 shares. The stock had previously closed at $124.64.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Wolfe Research restated an "outperform" rating and set a $110.00 price objective on shares of Celcuity in a research report on Thursday, March 12th. Wall Street Zen upgraded shares of Celcuity from a "sell" rating to a "hold" rating in a research report on Saturday, March 28th. Wells Fargo & Company assumed coverage on shares of Celcuity in a research report on Friday, December 12th. They set an "overweight" rating and a $126.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Celcuity in a research report on Wednesday, January 21st. Finally, Needham & Company LLC restated a "buy" rating and set a $122.00 price objective on shares of Celcuity in a research report on Thursday, March 26th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $109.88.

Celcuity Stock Performance

The firm's fifty day simple moving average is $110.16 and its 200 day simple moving average is $94.44. The company has a market capitalization of $5.67 billion, a price-to-earnings ratio of -30.92 and a beta of 0.41. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its earnings results on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.09. On average, sell-side analysts forecast that Celcuity, Inc. will post -2.62 EPS for the current year.

Insider Activity at Celcuity

In related news, Director Richard E. Buller sold 3,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total transaction of $330,810.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at approximately $745,425.20. This trade represents a 30.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the sale, the director owned 90,000 shares of the company's stock, valued at approximately $10,802,700. This represents a 18.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 15.77% of the company's stock.

Institutional Trading of Celcuity

Institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC raised its position in Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company's stock valued at $34,000 after acquiring an additional 319 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Celcuity during the fourth quarter valued at approximately $42,000. Ogorek Anthony Joseph NY ADV bought a new position in Celcuity during the third quarter valued at approximately $27,000. US Bancorp DE raised its position in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company's stock valued at $35,000 after acquiring an additional 143 shares in the last quarter. Finally, NBC Securities Inc. bought a new position in Celcuity during the fourth quarter valued at approximately $99,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.